Project Grant R56HL173123
Award Date
9/24/24
Completion Date
8/31/25
Dollars Obligated
$452K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to identify common and distinct metabolic and proteomic pathways associated with inflammation and fibrosis in pulmonary sarcoidosis. The $249,000 award to National Jewish Health will be used to conduct metabolomic and proteomic profiling of plasma samples from patients with fibrotic and non-fibrotic pulmonary sarcoidosis, as well as healthy...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $760,374 Project Grant to National Jewish Health to conduct an integrative metabolomics study on sarcoidosis diagnosis and progression. The study aims to identify blood-based diagnostic and prognostic signatures associated with pulmonary sarcoidosis, including differences by genetic ancestry and sex. Specifically, the project will incorporate single nucleotide...
This federal Project Grant award of $751,954 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research into investigating CXCR3 blockade as a potential precision therapy for cardiac sarcoidosis. The principal investigator will utilize single-cell multi-omics and T-cell receptor sequencing to define the key pathogenic T-cell subsets and interactions between adaptive and innate immunity that drive cardiac...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $127,875 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Oklahoma Medical Research Foundation (OMRF) to conduct a multi-omic characterization of immune cells in sarcoidosis. The project aims to advance sarcoidosis research by identifying molecular signatures and novel candidate genes associated with sarcoidosis susceptibility and disease burden. The research will leverage OMRF's expertise in immunology,...
This $807,188 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which administers the Allergy and Infectious Diseases Research program (CFDA 93.855), to The Ohio State University to conduct research on the redox regulation of sarcoidosis granulomas and fibrosis. The key objectives of this 2-year project are to: 1) determine if activation of the renin-angiotensin-aldosterone system (RAAS) and mineralocorticoid receptors (MR) promotes sarcoidosis...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on the mechanisms underlying lung injury, fibrosis, and susceptibility to bacterial infections. The key objectives are to study: 1) how epithelial cell signaling regulates fibrosis and interacts with myeloid cells, 2) the impaired innate immunity against...
This $651,019 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to elucidate the mechanisms behind dysfunctional epithelial repair processes that contribute to the development of pulmonary fibrosis. The research aims to identify factors driving aberrant epithelial cell states, determine the role of HIF signaling in preventing functional alveolar repair, and investigate niche-specific mechanisms regulating...
This federal Project Grant award in the amount of $116,625 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support a research project to characterize clinically relevant phenotypes related to osteoporosis and sarcopenia in chronic obstructive pulmonary disease (COPD). The key products and services to be delivered under this 2-year award include: Development and validation of automated CT-based methods to quantify static metrics of spine,...
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $605,678.00 to the University of South Alabama to conduct research on a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the concept that a pathway called "BRACR" (Base Oxidation and Repair Activated Chromatin Restructuring) is a fundamental component of the...